Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 551 to 560 of 2194 total matches.

Genvoya - A New 4-Drug Combination for HIV

   
The Medical Letter on Drugs and Therapeutics • Feb 15, 2016  (Issue 1488)
recommend that antiretroviral-naive patients infected with HIV-1 receive an INSTIbased regimen ...
The FDA has approved Genvoya (Gilead), a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) elvitegravir, the pharmacokinetic enhancer cobicistat, and the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) emtricitabine and tenofovir alafenamide, for treatment of HIV-1 infection in patients ≥12 years old. This is the first approval for tenofovir alafenamide (TAF), a tenofovir prodrug. Stribild, a fixed-dose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (TDF), was approved in 2012.
Med Lett Drugs Ther. 2016 Feb 15;58(1488):19-21 | Show Introduction Hide Introduction

Selexipag (Uptravi) for Pulmonary Arterial Hypertension

   
The Medical Letter on Drugs and Therapeutics • Feb 15, 2016  (Issue 1488)
and exercise capacity more than either drug alone.1 Data on the effectiveness of using other drug ...
The FDA has approved selexipag (Uptravi – Actelion), an oral selective prostacyclin IP receptor agonist, for treatment of pulmonary arterial hypertension (PAH). Treprostinil (Orenitram), an oral prostacyclin analog, was approved earlier for this indication.
Med Lett Drugs Ther. 2016 Feb 15;58(1488):21-3 | Show Introduction Hide Introduction

Patiromer (Veltassa) for Hyperkalemia

   
The Medical Letter on Drugs and Therapeutics • Feb 15, 2016  (Issue 1488)
in patients with bowel dysfunction or recent GI surgery.1-3 Taken orally, the drug may bind to other drugs ...
The FDA has approved patiromer (Veltassa – Relypsa), an oral potassium binder, for treatment of hyperkalemia. It is the first drug to be approved for this indication since the cation-exchange resin sodium polystyrene sulfonate (Kayexalate, and others) in 1958. Patiromer is not indicated for emergency correction of life-threatening hyperkalemia. Sodium zirconium cyclosilicate, another oral potassium binder, is currently being reviewed by the FDA; a decision on its approval is expected in May 2016.
Med Lett Drugs Ther. 2016 Feb 15;58(1488):23-4 | Show Introduction Hide Introduction

Correction: Drugs for Acne

   
The Medical Letter on Drugs and Therapeutics • Feb 15, 2016  (Issue 1488)
In Table 1 of our February 1, 2016 article Drugs for Acne (Med Lett Drugs Ther 2016; 58 ...
In Table 1 of our February 1, 2016 article Drugs for Acne (Med Lett Drugs Ther 2016; 58:13), the formulations for Differin, topical adapalene, should have been listed as 0.1% gel, cream, lotion; 0.3% gel (not 3% gel).
Med Lett Drugs Ther. 2016 Feb 15;58(1488):24 | Show Introduction Hide Introduction

Drugs for Rosacea

   
The Medical Letter on Drugs and Therapeutics • Feb 01, 2016  (Issue 1487)
The Medical Letter® on Drugs and Therapeutics Volume 58 (Issue 1487) February 1, 2016 Published ...
This common, chronic inflammatory facial eruption of unknown cause is more prevalent in women than in men. Rosacea is characterized by erythema and telangiectasia, and sometimes by recurrent, progressive crops of acneiform papules and pustules, usually on the central part of the face. Some patients develop granulomas and tissue hypertrophy, which may lead to rhinophyma (a bulbous nose), particularly in men. Blepharitis and conjunctivitis are common. Keratitis and corneal scarring occur rarely.
Med Lett Drugs Ther. 2016 Feb 1;58(1487):16-7 | Show Introduction Hide Introduction

Rolapitant (Varubi) for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting

   
The Medical Letter on Drugs and Therapeutics • Feb 01, 2016  (Issue 1487)
The Medical Letter® on Drugs and Therapeutics Volume 58 (Issue 1487) February 1, 2016 Published ...
The FDA has approved rolapitant (Varubi – Tesaro), an oral substance P/neurokinin 1 (NK1) receptor antagonist, for use with other antiemetics to prevent delayed nausea and vomiting associated with cancer chemotherapy in adults. It is the third substance P/NK1 receptor antagonist to be approved in the US; aprepitant (Emend) and netupitant (only available in combination with the 5-HT3 receptor antagonist palonosetron as Akynzeo) were approved earlier for prevention of both acute and delayed chemotherapy-induced nausea and vomiting.
Med Lett Drugs Ther. 2016 Feb 1;58(1487):17-8 | Show Introduction Hide Introduction

Addendum: Timing of Levothyroxine

   
The Medical Letter on Drugs and Therapeutics • Feb 01, 2016  (Issue 1487)
The Medical Letter® on Drugs and Therapeutics Volume 58 (Issue 1487) February 1, 2016 Published ...
In our October 26, 2015 article on drugs for hypothyroidism (Med Lett Drugs Ther 2015; 57:147), we said that levothyroxine should be taken on an empty stomach with a full glass of water 30-60 minutes (60 is preferable) before breakfast. We should have added that taking the drug consistently at bedtime, at least 3 hours after the last meal, is an alternative that some patients may find more convenient.
Med Lett Drugs Ther. 2016 Feb 1;58(1487):18 | Show Introduction Hide Introduction

Durlaza - A 24-Hour Extended-Release Aspirin

   
The Medical Letter on Drugs and Therapeutics • Jan 18, 2016  (Issue 1486)
at the end of the 24-hour dosing interval.1 An ER formulation that releases acetylsalicylic acid (ASA) over ...
The FDA has approved Durlaza (New Haven Pharmaceuticals), a 24-hour extended-release (ER) aspirin formulation available only by prescription, for secondary prevention of myocardial infarction (MI) and stroke.
Med Lett Drugs Ther. 2016 Jan 18;58(1486):7 | Show Introduction Hide Introduction

Fluad - An Adjuvanted Seasonal Influenza Vaccine for Older Adults

   
The Medical Letter on Drugs and Therapeutics • Jan 18, 2016  (Issue 1486)
adults; Fluzone High-Dose was the first.1 Fluad has been available in other countries for many years ...
The FDA has approved Fluad (Seqirus), an adjuvanted trivalent seasonal influenza vaccine, for immunization of adults ≥65 years old. It will become available later this year for use during the 2016-2017 influenza season. Fluad is the second influenza vaccine to be approved in the US specifically for older adults; Fluzone High-Dose was the first. Fluad has been available in other countries for many years.
Med Lett Drugs Ther. 2016 Jan 18;58(1486):8 | Show Introduction Hide Introduction

Talimogene Laherparepvec (Imlygic) for Unresectable Melanoma

   
The Medical Letter on Drugs and Therapeutics • Jan 18, 2016  (Issue 1486)
makes them good targets for intralesional viral immunotherapy.1,2 Talimogene laherparepvec (T ...
The FDA has approved talimogene laherparepvec (Imlygic – Amgen), a genetically modified herpes simplex virus, for intralesional treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma that has recurred following surgery. It is the first oncolytic virotherapy to become available in the US.
Med Lett Drugs Ther. 2016 Jan 18;58(1486):8-9 | Show Introduction Hide Introduction